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Background: Arthritis and musculoskeletal conditions are the leading cause of long-term work disability (WD), an
outcome with a major impact on quality of life and a high cost to society. The importance of decreased at-work
productivity has also recently been recognized. Despite the importance of these problems, few interventions have
been developed to reduce the impact of arthritis on employment. We have developed a novel intervention called
“Making It Work”, a program to help people with inflammatory arthritis (IA) deal with employment issues, prevent
WD and improve at-work productivity. After favorable results in a proof-of-concept study, we converted the
program to a web-based format for broader dissemination and improved accessibility. The objectives of this study
are: 1) to evaluate in a randomized controlled trial (RCT) the effectiveness of the program at preventing work
cessation and improving at-work productivity; 2) to perform a cost-utility analysis of the intervention.
Methods/Design: 526 participants with IA will be recruited from British Columbia, Alberta, and Ontario in Canada.
The intervention consists of a) 5 online group sessions; b) 5 web-based e-learning modules; c) consultations with an
occupational therapist for an ergonomic work assessment and a vocational rehabilitation counselor. Questionnaires will
be administered online at baseline and every 6 months to collect information about demographics, disease measures,
costs, work-related risk factors for WD, quality of life, and work outcomes. Primary outcomes include at-work productivity
and time to work cessation of > 6 months for any reason. Secondary outcomes include temporary work cessation,
number of days missed from work per year, reduction in hours worked per week, quality adjusted life year for the cost
utility analysis, and changes from baseline in employment risk factors. Analysis of Variance will evaluate the intervention’s
effect on at-work productivity, and multivariable Cox regression models will estimate the risk of work cessation associated
with the intervention after controlling for risk factors for WD and other important predictors imbalanced at baseline.
Discussion: This program fills an important gap in arthritis health services and addresses an important and costly
problem. Knowledge gained from the RCT will be useful to health care professionals, policy planners and arthritis
stakeholders.
Trial registration: ClinicalTrials.gov NCT01852851; registered April 13, 2012; first participant randomized on July 6, 2013.
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Work disability (WD) is a common and early outcome of
inflammatory arthritis (IA), with a major impact on quality
of life and a high cost to those affected, their families and so-
ciety [1,2]. Arthritis and musculoskeletal conditions are the
leading cause of long-term WD in many countries, includ-
ing Canada and the US [3,4]. Recent studies have also drawn
attention to the importance of decreased productivity while
at work, or presenteeism [5]. Despite the importance of the
problem, there has been little research on interventions to
reduce the impact of arthritis on employment [6-9]. Lack of
employment services has also been identified by people liv-
ing with arthritis as an important unmet need in qualitative
studies [10-12]. It represents an important gap from a clin-
ical care and a health services research perspective.
To close this care gap, we have developed and pilot tested
a novel intervention targeting employed people with IA, to
prevent WD and improve at-work productivity [13]. Our
“Employment and Arthritis: Making It Work Program” is
unique in that it combines the benefits of group sessions
and self-learning modules aimed at enhancing self-
management of work-related problems, and individualized
assessments by employment-related health professionals,
including an ergonomic assessment by an occupational
therapist (OT) and job retention vocational rehabilitation
counselling (VRC). Program development was based on a
strong theoretical background, the self-management ap-
proach proven effective in arthritis management [14,15]
and the precede-proceed model [16-18], a validated model
successfully used for developing health education programs.
Program content was selected to modify known risk factors
for WD and problems at work identified in initial focus
groups [10]. A proof of concept study of the intervention
showed favourable results after 12 months of follow up
[13]. The program has now been converted to a web-
based format to allow broader dissemination of the pro-
gram, and to address feedback from participants who
found it difficult to attend sessions at the end of a work
day, given the fatigue and difficulty commuting associated
with their IA. This evolution is consistent with recent
trends in adult learning, health education and in self-
management programs [19-31].
The objectives of this study are: 1) to evaluate, in a ran-
domized controlled trial (RCT), the effectiveness of the pro-
gram at preventing work cessation and improving at-work
productivity compared to a control group receiving usual
care; 2) to perform a cost-utility analysis of the intervention.
Methods/design
Study design
Our study design is consistent with CONSORT recom-
mendations for RCTs, 2010 update [32] and extension
for trials of non-pharmacological treatments [33]. Partic-
ipants will be stratified by location and arthritis type andrandomized 1:1 to receive either our program, or “usual
care” as initiated by their physician and supplemented
by printed material about work and arthritis. Partici-
pants will be followed for 5 years, the estimated time re-
quired, according to our power calculations, to observe
a difference in work cessation similar to that in Allaire’s
RCT [34]. After 2 years, analysis of our first primary out-
come, at-work productivity, will be performed, along
with an interim analysis of the second primary outcome,
work cessation. If a significant difference in work cessa-
tion is observed between the two groups, the RCT will
be terminated prematurely. Because of the nature of the
intervention, participants cannot be blinded. Ethics ap-
proval was obtained from the University of British
Columbia Research Ethics Board (H11-03527).
Study sample
526 participants will be recruited from British Columbia,
Alberta, and Ontario. To be eligible to participate, individ-
uals must: 1) have a physician confirmed diagnosis of IA
(including rheumatoid arthritis, psoriatic arthritis, sys-
temic lupus erythematosus, or spondyloarthropathies); 2)
Be between the ages of 18 and 59 years; 3) Be able to read
and write in English without the assistance of a translator;
4) Be currently employed (full time, part time, self-
employed, or contract work); 5) Be at risk of job loss, de-
fined as answering yes to: “Do you have any concern about
your arthritis affecting your ability to work now, or in the
next five years?”; 6) Have access to a personal computer
with high-speed, wired-in internet connection and have
access to, or willingness to purchase, a webcam and head-
set for the virtual group meetings and VRC assessments;
7) Be willing to travel for one visit with an OT.
Randomization
Randomization will be stratified by study centre (3 levels)
and type of arthritis (4 levels). In each stratum, we will use
blocked randomization, with random and variable block
sizes, to ensure optimal balance between trial arms, while
avoiding the risk of study personnel ‘guessing’ the next al-
location. Randomization will be performed centrally, in
Vancouver; by the biostatistician (CG) using a customized
program in the R programming language, after the study
coordinator has confirmed eligibility and received informed
consent. To ensure concealment of the randomization list
from those making eligibility decisions, allocations will be
available for one patient at a time.
Intervention
The intervention consists of three components:
1) Five interactive web-based eLearning modules,
completed individually by participants in between the
biweekly group sessions. The modules cover relevant
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IA, dealing with fatigue and stress at work, effective
communications skills, disclosing one’s arthritis
diagnosis, optimizing interpersonal relationships at
work, job accommodations, and vocational counselling.
In addition to providing didactic information, reflective
exercises improve self-awareness and allow participants
to apply the concepts learned to their own personal
situation. Self-management techniques and other
relevant skills are also taught and practiced.
2) Five 2-hour biweekly group sessions conducted as
virtual real-time group meetings, with 10–12
participants per group, led by a facilitator with
knowledge of arthritis and experience leading
self-management or education programs. The group
interactions allow participants to share experiences,
learn from each other, practice skills, and report back
to the group on the progress of their action plans.
These interactions were highly valued by participants
of our pilot test, who described experiencing validation
by hearing from others living similar situations, benefit-
ing from others’ experiences and solutions, receiving
peer support, and being motivated to implement
changes by having to report back to the group [13].
3) Consultations with an OT and a VRC. After
completing the web-based modules and group
meetings, participants have an in-person consultation
with an OT for an ergonomic assessment of their
work. The OT uses a standardized tool we developed
for people with IA called the Ergonomic Assessment
Tool for Arthritis (EATA) [35], to identify ergonomic
problems and risks, and recommend ergonomic
modifications as job accommodations. A telephone
follow-up is performed one month later to discuss
implementation of recommendations and help
overcome barriers. A vocational counsellor provides
“job retention” VRC, using a standardized guide
developed for our program, with an initial consultation
performed using web technology and a follow-up one
month later by telephone. The assessment focuses on
identifying problems at work and developing solutions,
evaluating the need for job accommodations and
helping in the process of requesting and obtaining
job accommodations, short and long-term planning
such as determining if additional training would
facilitate long-term goals, as well as discussing
individual issues such as the decision to disclose
one’s arthritis, or dealing with interpersonal
difficulties with co-workers or supervisors.
Control group
The control group will receive printed materials providing
information about arthritis and employment available from
arthritis websites and non-profit organizations. They willalso receive “usual care” from their physicians and allied
health professionals. Data will be collected, in follow-up as-
sessments, on information and support received to address
employment issues. To minimize loss to follow-up, all con-
trols will be offered the intervention at study end.
Data collection
Data will be collected on demographics, disease variables,
co-morbidities, quality of life, costs, work-related risk fac-
tors for WD, and work outcomes, using a self-administered
online questionnaire. Work outcomes, costs and quality of
life will be assessed every 6 months, and other data once
yearly. To evaluate co-interventions received in both
groups, data will also be collected every 6 months about IA
treatment received, “usual care” received from physicians
and allied health professionals, information sought about
employment issues, use of services specifically targeted at
employment, and job accommodations made.
Outcome measures
Primary work outcomes
The first primary outcome will be presenteeism, or at-
work productivity, measured over 2 years, using the
Work Instability Scale (WIS-RA) [36]. Developed for
RA, the WIS measures mismatch between functional
ability and work demands, and was designed to identify
individuals at high risk of work loss warranting referral
for vocational assessment. It has been shown to have
good psychometric properties, including construct valid-
ity [37], and be effective at predicting future work transi-
tions [38]. However, a drawback of the WIS is that it does
not permit the calculation of associated costs. Therefore,
for the purpose of the cost-utility analysis, at-work prod-
uctivity will be measured using the Work Productivity and
Activity Impairment – Specific Health Problem (WPAI-
SHP) scale [39]. The WPAI-SHP measures overall impair-
ment in activities (from work time missed, impairment
while working, and activity impairment outside of work)
due to a health problem, expressed as percent impairment,
which can be used to calculate associated cost. Statistically
significant improvement in both the WIS and the WPAI-
SHP were observed in our pilot study.
The second primary outcome will be time to work ces-
sation, measured over 5 years of follow up. Work cessation
is defined as complete cessation of work for more than
6 months, the standard duration used by insurance com-
panies to define permanent WD, and also consistent with
definitions of WD in the employment literature [40]. This
definition will capture WD from all health reasons (i.e. not
only related to arthritis), including early retirement, work
cessation for personal reasons, and prolonged unemploy-
ment periods when people are looking for another job, but
will not capture temporary WD, sick leave, or short pe-
riods of unemployment of less than 6 months duration.
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arthritis related work cessation is an issue of debate in the
arthritis employment literature. Because of difficulties at-
tributing work cessation to a single cause (i.e. the decision
is often multifactorial and arthritis may have played some
role in the decision), it is generally recommended that all-
cause work cessation be measured in studies including a
control group [41].Secondary work outcomes
Secondary work outcomes will include: 1) temporary
work cessation for any reason (i.e. sick leave, temporary
WD, and short periods of unemployment lasting more
than 2 months but less than 6 months); 2) occasional
work absence (i.e. number of days missed from work per
year); 3) reduction in usual amount of time worked (i.e.
reduction in hours per week worked); 4) At-work prod-
uctivity measured using a new scale currently being de-
veloped and validated based on a combination of the
Workplace Activity Limitations Scale (WALS) and Work
Limitations Questionnaire (WLQ); 5) Quality adjusted
life year (QALY), will be measured using EQ-5D and
SF-6D, 2 years post intervention, for the cost-utility
analysis; 6) Changes from baseline in job satisfaction,
self-efficacy at work, work-related risk factors for WD
(job physical demand, job autonomy, difficulty commut-
ing, self-employment and support from co-workers, em-
ployers and family), job accommodations, and job type
will also be evaluated, as exploratory analyses, in an at-
tempt to understand the effect of the intervention on
mediators of work disability.Sample size and analysis
Sample size was calculated for the primary outcome re-
quiring the largest sample, i.e. time to work cessation. It
was performed with PASS software [42] for time-to-
event analyses. We assumed 5 years of follow-up and a
rate of work cessation of 12.77% per year in the control
group, based on the 40% work loss observed in controls
over 4 years in Allaire’s RCT of VRC [34], and assuming
an exponential distribution of time to work loss. A sample
size of 420 subjects (210 per group) completing the study
is necessary for 80% power, a 2-tailed Cox model-based
score test, equivalent to the logrank test, at alpha = 0.05,
to detect a 35% relative risk reduction (HR = 0.65) in the
intervention vs. control group, which was considered a
minimally clinically important difference (MCID), and is
moderately conservative compared to the 42% risk reduc-
tion observed in Allaire’s study (HR = 0.58, 95% CI:0.34-
0.99) [34]. Assuming 20% loss to follow-up, we will recruit
a total of 526 subjects (263 per group). This sample will
ensure adequate power for our other primary outcome, at-
work productivity.Appropriate descriptive statistics will be used to meas-
ure baseline characteristics of the two groups. Analysis
of treatment effectiveness will rely on intention-to-treat
(ITT) approach, so that all patients initially randomized
will be included in the analysis, regardless of their com-
pliance or drop-outs.
For the analysis of our first primary outcome, at-work
productivity measured as a continuous variable will be
tested for normality using the Shapiro-Wilk test [43]. If
normality assumption is rejected, an appropriate trans-
formation (e.g. such as logarithmic) will be employed to
obtain an approximately normal distribution. Next, an
Analysis of Variance (ANOVA) will evaluate the effect of
the intervention on WIS measures at 2 years, adjusting
for the 12 strata and blocking. We will also consider an
Analysis of Covariance model after inspection of the
baseline values in both treatment arms for factors such
as WIS score, duration of disease, physician providing
RA care, age, gender and risk factors for WD. If differ-
ences at baseline are observed, we will consider them as
covariates. Since the power of these analyses will likely
be less than the original ANOVA, post hoc power ana-
lyses will be conducted if these appear to be clinically
meaningful adjustments.
In the analysis of our second primary outcome, time-
to-event (survival) methodology will compare the risk of
work cessation in the intervention and control groups.
Subjects employed until end of their follow-up (study
end, death or time of loss to follow-up, whichever occurs
earlier) will be censored. First, Kaplan Meier ‘survival
curves’ and logrank test will estimate and compare the
proportions of subjects who continue being employed in
the intervention and control groups. Next, multivariable
Cox Proportional Hazards (PH) regression model [44]
will be employed to estimate the adjusted Hazard Ratio
(HR) with 95% CI, associated with the intervention after
controlling for potential risk factors for WD that may be
imbalanced at baseline, despite randomization, and for
other important predictors, such as age, gender, RA dur-
ation at baseline, and physician providing RA care, whose
omission could induce bias toward the null in time-to-
event analyses [45]. We will use a flexible extension of the
Cox model [46], which will allow us to estimate how the
HR reduction due to intervention changes over time, if
the proportional hazard assumption (that the intervention
effect remains constant over time) is rejected.
For analyses of secondary outcomes, time-to-event
methods will be employed for dichotomous outcome vari-
ables (e.g. time to temporary work cessation), and com-
parison of means between intervention and control
groups will be employed for continuous variables (e.g.
measures of absenteeism, job satisfaction, self-efficacy
and risk factors for WD), as described above for the
primary outcomes.
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tion), an interim analysis will be performed at 2 years of
follow-up. We will use the same method as for the pri-
mary analysis and will employ the PETO criteria to adjust
the overall type I error for multiple testing [47]. Specific-
ally, we will use a conservative type I error of 0.001 for the
interim analysis, which will allow us to maximize the
power of the final analyses of the 5 year outcomes, which
will employ the conventional 0.05 significance level.
We will also examine the incremental costs and benefits
of receiving the intervention versus standard of care. Both
a cost-effectiveness analysis and a cost-utility analysis will
be performed. The outcome of our analysis will be the in-
cremental cost-effectiveness ratio (ICER), which is the dif-
ference between the mean costs of providing competing
interventions divided by the difference in effectiveness.
Based on the primary outcome of the RCT, we will deter-
mine the incremental cost of the intervention per work
cessation avoided relative to standard treatment. Because
cost-effectiveness analyses are not robust to quantity or
quality of life, we will also conduct a cost-utility analysis,
where the primary outcome is the quality adjusted life year
(QALY). Using health utilities measured by the EQ-5D and
SF-6D, we will conduct a cost-utility analysis in which the
incremental cost of the intervention relative to standard
therapy per QALY gained will be determined. Important
aspects of economic evaluations conducted alongside an
RCT are excluding protocol driven costs, and dealing with
missing data due to attrition. We will follow recommenda-
tions by the International Society for Pharmacoeconomics
and Outcomes Research for missing cost and effectiveness
data. We will use a combination of imputation and boot-
strapping to quantify uncertainty due to missing values
and finite study sample size. We will use propensity scores,
stratified by treatment group, for imputing missing costs
and effectiveness data due to attrition.
Limitations
Limitations are those inherent to the study design and
intervention. Participating in research, especially complet-
ing questionnaires may trigger awareness of problems,
leading to more active coping behaviour than “usual” in
the control group. The un-blinded nature of our interven-
tion increases the risk of contamination (administration of
part of the intervention to the control group, especially re-
ferral to OT and VRC) and unequal co-intervention (i.e.
unequal administration of additional measures to deal
with employment problems). However, these issues would
reduce our ability to observe a difference between inter-
vention and control group and therefore would constitute
a conservative bias. Also, our recruitment strategy (i.e.
avoiding prospective enrolment of consecutive patients
as they are seen by rheumatologists) was specifically
designed to limit these risks. We will collect data todocument the extent to which contamination or co-
intervention occurs.
Our intervention is a complex one involving several
components. Our study was designed to evaluate the ef-
fectiveness of the intervention as a whole and not to
evaluate the relative effectiveness of each component.
Five years of follow-up is long and increases the risk of
loss to follow-up. However, this is the time required to
evaluate work cessation. The importance of this out-
come, in terms of quality of life and economic impact, at
the personal and societal level, warrants the difficulty of
a lengthy trial. Preventing work disability is the outcome
most relevant to health policy planners, employers, in-
surance companies, and will influence the decision to
fund the program as part of the multidisciplinary ser-
vices offered to people with arthritis. We have designed
strategies to enhance retention.
Discussion
We have created a novel program for people with IA to
improve an aspect of disease management too often ig-
nored by health professionals, the management of employ-
ment issues. Our program is unique in that it combines
the benefit of group sessions focused on improving self-
management, with assessments by health professionals
specifically addressing employment. The web-based tech-
nology for delivering our program is at the leading edge of
trends in the field of adult education and self-management
programs, and offers a number of advantages for facilitat-
ing both learning and program dissemination.
Our research initiative is one of few worldwide to develop
and test the effectiveness of interventions specifically tar-
geted at employment. Before our program can be imple-
mented as part of routine care, it is important that its
effectiveness be rigorously evaluated. The knowledge gained
from this RCT will be useful for health care professionals
to refer to the program, for health care policy planners to
agree to fund it as part of multidisciplinary arthritis ser-
vices, and for arthritis stakeholders to endorse the program,
promote it and help disseminate it widely. By preventing
WD, our program has the potential for great cost savings to
society and huge personal impact on people’s lives.
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